Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 9,167 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $3.55, for a total value of $32,542.85. Following the sale, the chief executive officer owned 119,422 shares of the company’s stock, valued at approximately $423,948.10. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cadrenal Therapeutics Trading Down 2.6%
CVKD opened at $2.98 on Thursday. The stock has a fifty day moving average price of $4.79 and a 200 day moving average price of $6.29. Cadrenal Therapeutics, Inc. has a 1 year low of $2.55 and a 1 year high of $14.64. The stock has a market cap of $8.55 million, a price-to-earnings ratio of -0.53 and a beta of 1.59.
Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.47. As a group, sell-side analysts forecast that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current fiscal year.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Cadrenal Therapeutics
Institutional Trading of Cadrenal Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. DRW Securities LLC bought a new stake in shares of Cadrenal Therapeutics during the 4th quarter worth about $171,000. Citadel Advisors LLC acquired a new stake in Cadrenal Therapeutics in the 3rd quarter worth approximately $274,000. JPMorgan Chase & Co. acquired a new stake in Cadrenal Therapeutics in the 3rd quarter worth approximately $103,000. Finally, Geode Capital Management LLC lifted its holdings in Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the last quarter. Institutional investors and hedge funds own 7.92% of the company’s stock.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Read More
- Five stocks we like better than Cadrenal Therapeutics
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
